About this trial
The investigators propose a randomized controlled trial comparing BP and roux limb lengths measuring 30 and 15% respectively of patient's total small bowel length versus current standard practice using fixed lengths. The findings would provide further insight into feasibility of standardizing RYGB limb lengths and optimizing resultant weight loss and metabolic effects. The investigators hypothesize RYGB with ratio-adjusted limb lengths (aRYGB) will result in higher total weight loss and resolution of metabolic syndrome comorbidities, including diabetes, hyperlipidemia, and hypertension compared to standard fixed-length RYGB (sRYGB). The study will also utilize the Short Form Rand 36-Item Health Survey (SF36) to determine differences in postoperative quality of life metrics.
Eligibility criteria
Qualifiers
morbidly obese patients (defined by BMI between 40 and 60).
Patient who understands and accepts the need for a long-term follow-up.
Patient who agrees to be included in the study
Disqualifiers
individuals unable to understand and sign a written consent form
patients with history of previous bariatric surgery procedures
presence of a severe and evolutive life threatening pathology unrelated to obesity
previous gastric or small bowel resection
Trial design
Treatments tested in this trial
- Surgery
Treatment groups
Sponsors and collaborators
Salvador Navarrete
Lead sponsor
The Cleveland Clinic
Sponsor institution